ORCHPHARMA
Orchid Pharma Limited (ORCHPHARMA) Stock Analysis
Orchid Pharma Limited develops and manufactures generic injectables, oral solids, and APIs for regulated and emerging markets. It has expertise in cephalosporins and sterile formulations. The company supplies global generics players and institutions. It is listed on Indian stock exchanges after restructuring of its pharma operations.
Healthcare › Drug Manufacturers - Specialty & Generic
₹984.00
-0.61% 1W | +37.30% 52W
Market Cap
5.0k CR
P/E Ratio
611.1
52W High
₹1143.5
52W Low
₹480
Div. Yield
0%
Beta
0.5
50 DMA
₹1004.4
200 DMA
₹799.2
Profit Margin
3.5%
Inst. Own.
17.3%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182.92 | 198.76 | 220.59 | 217.10 | 244.41 | 222.70 | 217.34 | 237.48 | 263.19 | 193.52 | 207.27 | 368.33 | 304.17 |
| Expenses | 160.78 | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 268.84 | 194.99 | 205.71 | 338.17 | 290.17 |
| Operating Profit | 22.14 | 23.30 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14.00 |
| OPM % | 12.10% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% |
| Other Income | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.90 | 11.57 | 10.77 | -1.50 | 7.55 | 1.83 |
| Interest | 5.55 | 3.80 | 3.54 | 3.47 | 3.50 | 3.33 | 3.80 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.90 | 9.03 | 10.90 | 10.95 |
| Profit before tax | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.90 | 22.45 | 19.10 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0.00% | 0.00% | 0.00% | -10.27% | -0.53% | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% |
| Net Profit | 9.40 | 19.80 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS in Rs | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
| Metric | Mar 201518m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Expenses | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 1,247 | 1,185 | 1,029 |
| Operating Profit | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 18% | 20% | 0.4% | 3.6% | -2.0% | -6% | 7% | 10% | 13% | 14% | 11% | 3.9% | 4.1% |
| Other Income | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 26 | 15 | 19 |
| Interest | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 13 | 9 | 11 |
| Depreciation | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 42 | 43 | 40 |
| Profit before tax | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 122 | 10 | 12 |
| Tax % | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -8% | -2% | |
| Net Profit | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS in Rs | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 26.63 | 1.96 | 2.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 23.0% | 22.0% | 4.0% |
| Profit CAGR | 53.0% | 17.0% | 8.0% |
Shareholding Pattern
Promoters69.84%
FIIs1.56%
DIIs19.04%
Public9.57%
Promoters69.84%
FIIs1.17%
DIIs19.38%
Public9.61%
Promoters69.84%
FIIs0.87%
DIIs20.24%
Public9.04%
Promoters69.84%
FIIs0.80%
DIIs20.75%
Public8.62%
Promoters74.45%
FIIs0.92%
DIIs17.54%
Public7.08%
Promoters89.96%
FIIs0.81%
DIIs2.62%
Public6.60%
Promoters69.84%
FIIs1.96%
DIIs17.73%
Public10.47%
Promoters69.84%
FIIs2.69%
DIIs20.10%
Public7.37%
Promoters69.84%
FIIs0.87%
DIIs20.24%
Public9.04%
Promoters74.45%
FIIs0.92%
DIIs17.54%
Public7.08%
ORCHPHARMA
Holdings Analysis
Key strengths & risk signals
67
Overall
57
Fundamental
77
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (984.0) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.6% (1 week), 4.0% (1 month), 2.8% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (1004.4) is above 200-day average (799.2) - positive signal.
GOOD YEAR! Stock gained 37.3% in the last year.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 172,329 vs down days: 78,815. Ratio: 2.19x
Fundamental & Technical Analysis
67Overall
57Fundamental
77Technical
Fundamental Breakdown
Growth Quality
17/30
Revenue CAGR: 22.3% (EXCELLENT, 15/15). Profit CAGR: -40.1% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 3.5% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 5.54% public ownership - strong promoter/institutional control.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 3 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1004.4) is above 200-day average (799.2) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (984.0) above 200-day but below 50-day.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
GOOD YEAR! Stock gained 37.3% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 172,329 vs down days: 78,815. Ratio: 2.19x
RSI
3/5
NEUTRAL! RSI at 46.2 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 76.0% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.6% (1 week), 4.0% (1 month), 2.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
ORCHPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-24 | Concall PDF | |
| Q4FY262026-06-01 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORCHPHARMA | ₹984.00 | 611.1 | 3.5% | 22.3% | -40.1% | +37.3% | 67 | APPROACHING RESISTANCE | -156.1% | -86.6% | +15.6% | +28.0% |
| GUJTHEM | ₹363.50 | 81.3 | 28.0% | 3.8% | -7.0% | -9.7% | 58 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| RPGLIFE | ₹2,719.20 | 37.6 | 16.3% | 11.3% | 19.4% | +27.6% | 75 | APPROACHING SUPPORT | +17.1% | +3.0% | +15.9% | +10.6% |
| GUFICBIO | ₹406.30 | 55.5 | 7.5% | 6.1% | -6.9% | +15.7% | 60 | BREAKDOWN | +70.2% | +1.8% | +16.6% | +3.6% |
| AARTIDRUGS | ₹413.30 | 19.7 | 7.1% | -2.3% | 5.4% | -17.9% | 57 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| UNICHEMLAB | ₹531.10 | 12.3 | 13.2% | 18.4% | – | +12.3% | 64 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
Data from TradeAlone · Updated daily
